As the race to find a cure for the deadly Coronavirus is still on, Bharat Biotech has successfully developed COVAXIN, a vaccine for COVID-19. The Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials of the vaccine.
The human clinical trials are scheduled to start across India in July 2020.
Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV) developed COVAXIN.
The SARS-CoV-2 strain was isolated in NIV, Pune, after which it was transferred to Bharat Biotech. The indigenous inactivated vaccine was developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India.